- Home
- CION vs DCTH Comparison
CION vs DCTH Comparison
Compare CION & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CION
- DCTH
- Stock Information
- Founded
- CION 2011
- DCTH 1988
- Country
- CION United States
- DCTH United States
- Employees
- CION N/A
- DCTH N/A
- Industry
- CION Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- CION Finance
- DCTH Health Care
- Exchange
- CION Nasdaq
- DCTH Nasdaq
- Market Cap
- CION 491.6M
- DCTH 518.0M
- IPO Year
- CION N/A
- DCTH N/A
- Fundamental
- Price
- CION $9.45
- DCTH $11.63
- Analyst Decision
- CION Sell
- DCTH Strong Buy
- Analyst Count
- CION 2
- DCTH 4
- Target Price
- CION $11.50
- DCTH $22.75
- AVG Volume (30 Days)
- CION 525.6K
- DCTH 476.1K
- Earning Date
- CION 05-08-2025
- DCTH 05-13-2025
- Dividend Yield
- CION 16.35%
- DCTH N/A
- EPS Growth
- CION N/A
- DCTH N/A
- EPS
- CION 0.63
- DCTH N/A
- Revenue
- CION $252,432,000.00
- DCTH $37,205,000.00
- Revenue This Year
- CION N/A
- DCTH $128.78
- Revenue Next Year
- CION N/A
- DCTH $54.07
- P/E Ratio
- CION $14.93
- DCTH N/A
- Revenue Growth
- CION 0.57
- DCTH 1701.69
- 52 Week Low
- CION $8.51
- DCTH $4.26
- 52 Week High
- CION $12.71
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- CION 40.16
- DCTH 44.80
- Support Level
- CION $8.54
- DCTH $11.20
- Resistance Level
- CION $9.39
- DCTH $11.81
- Average True Range (ATR)
- CION 0.42
- DCTH 0.98
- MACD
- CION 0.02
- DCTH 0.04
- Stochastic Oscillator
- CION 45.85
- DCTH 51.25
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.